By Amina Niasse NEW YORK (Reuters) -Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit ...

Cigna now offers employers $200 Wegovy, Zepbound copay option. The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers. ... which caps monthly out-of-pocket costs at $200 for Wegovy and Zepbound, ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs ...

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, ... and Zepbound (tirzepatide) will not exceed $200. Wegovy has a list price of $1,350 per month, ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 drugs. ... Zepbound at $200.

Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will make the medicines available to more patients.. Under the new option ...

Cigna also posted first quarter results well above analyst forecasts. On Friday, ... but that other GLP-1s, such as Eli Lilly’s Zepbound, could be more expensive.

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced ...